Takeda Gains Approval For HYQVIA In Japan To Treat Immunodeficiency
Takeda Gains Approval For HYQVIA In Japan To Treat Immunodeficiency
武田獲批在日本使用HYQVIA治療免疫缺陷
- HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia
- Administration of Recombinant Human Hyaluronidase Prior to Immunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More Flexibility
- Approval Expands Takeda's Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company's Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan
- HYQVIA [免疫球蛋白注射液 10%（人用）與重組人透明質酸酶] 是日本首個也是唯一一個獲批准用於無丙種球蛋白血癥和低丙種球蛋白血癥的經輔導皮下免疫球蛋白（fSCIG）。
- 在免疫球蛋白之前使用重組人透明質酸酶，可以促進大劑量的皮下注射，可能減少注射頻率，併爲患者提供更多靈活性。
- 批准擴展了武田藥品的差異化免疫球蛋白療法組合，反映了公司致力於爲日本患者提供高質量血漿衍生療法的承諾。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間